Tiziana Life Sciences
Clinical-stage biopharmaceutical company developing alternative routes of immunotherapy for neuroinflammatory and neurodegenerative diseases. Core development focuses on fully human monoclonal antibodies delivered via non-invasive routes (intranasal, oral) alongside small-molecule oncology assets. Operates with academic clinical collaborators and pursues IND filings, expanded access programs and patent protection.
Industries
Nr. of Employees
small (1-50)
Tiziana Life Sciences
Products
Foralumab
A fully human anti-CD3 monoclonal antibody under clinical development for intranasal, oral and subcutaneous administration to induce regulatory T cells and reduce CNS inflammation.
Anti-IL-6R monoclonal antibody (TZLS-501)
A fully human monoclonal antibody targeting the interleukin-6 receptor intended to modulate IL-6-driven inflammation, evaluated for pulmonary and systemic inflammatory conditions.
Milciclib
Orally administered small-molecule multi-kinase inhibitor with clinical data from Phase 1–2 studies in solid tumors and thymic cancer; being evaluated in additional oncology indications and combinations.
Foralumab
A fully human anti-CD3 monoclonal antibody under clinical development for intranasal, oral and subcutaneous administration to induce regulatory T cells and reduce CNS inflammation.
Anti-IL-6R monoclonal antibody (TZLS-501)
A fully human monoclonal antibody targeting the interleukin-6 receptor intended to modulate IL-6-driven inflammation, evaluated for pulmonary and systemic inflammatory conditions.
Milciclib
Orally administered small-molecule multi-kinase inhibitor with clinical data from Phase 1–2 studies in solid tumors and thymic cancer; being evaluated in additional oncology indications and combinations.
Services
Clinical development of intranasal biologics
Design and conduct of clinical studies for nasal administration of biologics, including dose-ranging, imaging and immuno-biomarker endpoints.
Expanded access and compassionate use management
Assessment and provisioning of investigational drugs to individual patients outside clinical trials following regulatory and ethical requirements.
Clinical supply and product development partnerships
Partnerships for product development and clinical supply to support IND submissions and study execution, including coordination with contract manufacturers.
Clinical development of intranasal biologics
Design and conduct of clinical studies for nasal administration of biologics, including dose-ranging, imaging and immuno-biomarker endpoints.
Expanded access and compassionate use management
Assessment and provisioning of investigational drugs to individual patients outside clinical trials following regulatory and ethical requirements.
Clinical supply and product development partnerships
Partnerships for product development and clinical supply to support IND submissions and study execution, including coordination with contract manufacturers.
Expertise Areas
- Intranasal and mucosal immunotherapy
- Monoclonal antibody development and translational immunology
- Clinical trial management (Phase 1–2) and safety monitoring
- Neuroinflammation and CNS therapeutics
Key Technologies
- Intranasal drug delivery
- Enteric-coated oral formulations
- Fully human monoclonal antibodies
- TSPO-PET imaging